Monopar Therapeutics (MNPR) Change in Acquisitions & Divestments (2023 - 2025)

Monopar Therapeutics has reported Change in Acquisitions & Divestments for 3 years, with the latest figure at $16.1 million in Q4 2025.

• Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $16.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.7 million (up 2304.31% YoY) and the FY2025 annual result came in at $23.7 million, up 2304.31% from the prior year.
• Change in Acquisitions & Divestments advanced to $16.1 million in Q4 2025 per MNPR's latest filing, from $3.6 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $16.1 million in Q4 2025 and troughed at $985730.0 in Q3 2024.
• A 3-year average of $4.2 million and a median of $3.0 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments tumbled 66.66% in 2024, then jumped 265.21% in 2025.
• Over 3 years, Change in Acquisitions & Divestments stood at $3.0 million in 2023, then tumbled by 66.71% to $985730.0 in 2024, then jumped by 1533.31% to $16.1 million in 2025.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $16.1 million, $3.6 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.